🔗 Visit the ClinicalTrials.gov page for NCT02289833
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Refining the treatment of NSCLC according to histological and molecular subtypes. | Nat Rev Clin Oncol | 2015 | 1.24 |
| 2 | Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. | Ann Oncol | 2015 | 1.12 |
| 3 | Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. | Front Oncol | 2016 | 0.79 |